We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dade Behring Acquires Rights to Cardiac Marker

By HospiMedica staff writers
Posted on 20 Feb 2003
A non-exclusive license under patent rights to develop, manufacture, and market immunoassays that detect a key marker of congestive heart failure (CHF) has been granted to Dade Behring (Deerfield, IL, USA) by Roche Diagnostics (Basel, Switzerland). More...
The marker is NT-proBNP (N-terminal prohormone brain natriuretic peptide).

BNP is secreted by the left ventricle when the heart is unable to pump blood efficiently. BNP dilates blood vessels and promotes sodium and water loss, reducing fluid load on the heart. Synthetic BNP (nesiritide) does not necessarily allow doctors to differentiate between elevated BNP levels due to drug treatment or due to ventricular dysfunction. In contrast, proBNP measures a hormone released when BNP is cleaved from its precursor, proBNP.

Elevated plasma NT-proBNP indicates the presence of heart failure and provides information about its severity. Also, NT-proBNP levels can help doctors identify left ventricular dysfunction, thereby allowing them to differentiate between heart failure and lung disorders with similar symptoms.

"This license enables Dade Behring, a market leader in clinical diagnostics for cardiac disease, to access an important new marker for use in the early detection and treatment of CHF,” said Jim Reid-Anderson, chairman, president, and CEO of Dade Behring.





Related Links:
Dade Behring
Roche

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.